探讨PCSK9单克隆抗体的安全性和耐受性

Study on the Safety and Tolerance of PCSK9 Monoclonal Antibody

枯草杆菌蛋白酶原/可信9(PCSK9)抑制剂是自2003年发现PCSK9蛋白以来开发的新药。除了背景他汀类药物治疗外,它们还将低密度脂蛋白胆固醇(LDL-C)降低到前所未有的水平,并在改善心脑血管事件方面显示出令人鼓舞的结果。本文综述了有关PCSK9的发现及生理作用机制,特别关注其安全性和耐受性,还讨论了极低密度脂蛋白胆固醇浓度的安全性。

Bacillus subtilis Proteinogen/Trust 9(PCSK9) inhibitor is a new drug developed since the discovery of PCSK9 protein in 2003. In addition to background statins, they also reduce low density lipoprotein cholesterol(LDL-C) to unprecedented levels and show encouraging results in improving cardiovascular and cerebrovascular events. In this paper, the discovery and physiological mechanism of PCSK9 are reviewed, with special attention to its safety and tolerance, and the safety of very low density lipoprotein cholesterol concentration is also discussed.